|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,660.00 KRW | +1.46% |
|
+0.24% | -2.86% |
| 12-11 | DongKook Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 18, 2026 | CI |
| 12-11 | Dongkook Pharmaceutical to divest 7 billion won worth of own shares | RE |
| Capitalization | 745B 505M 430M 399M 375M 698M 45.94B 748M 4.6B 1.82B 21.84B 1.89B 1.85B 79.71B | P/E ratio 2025 * |
10.7x | P/E ratio 2026 * | 9.27x |
|---|---|---|---|---|---|
| Enterprise value | 719M 487K 415K 384K 361K 673K 44.29M 722K 4.44M 1.75M 21.06M 1.82M 1.79M 76.85M | EV / Sales 2025 * |
0.78x | EV / Sales 2026 * | 0.69x |
| Free-Float |
53.85% | Yield 2025 * |
1.32% | Yield 2026 * | 1.44% |
| 1 day | +1.46% | ||
| 1 week | +0.24% | ||
| Current month | -2.86% | ||
| 1 month | -6.82% | ||
| 3 months | -9.99% | ||
| 6 months | -8.56% | ||
| Current year | -2.86% |
| 1 week | 16,390 |  | 16,760 |
| 1 month | 16,390 | | 18,070 |
| Current year | 16,390 | | 17,720 |
| 1 year | 14,400 | | 20,450 |
| 3 years | 13,000 | | 20,600 |
| 5 years | 13,000 | | 33,650 |
| 10 years | 9,340 | | 36,150 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joon-Ho Song
CEO | Chief Executive Officer | 58 | 24/03/2022 |
Yoon-Hwan Son
AUD | Comptroller/Controller/Auditor | 67 | - |
Jae-Seong Koo
PRN | Corporate Officer/Principal | 63 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Gi-Beum Kwon
CHM | Chairman | 58 | - |
Joon-Ho Song
BRD | Director/Board Member | 58 | 24/03/2022 |
Park Kwon
BRD | Director/Board Member | 83 | 23/03/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.46% | +0.24% | +8.04% | +0.97% | 505M | |
| +0.28% | -3.33% | +43.48% | +200.89% | 932B | |
| -0.21% | +2.13% | +48.41% | +29.32% | 526B | |
| -0.14% | -3.04% | +24.76% | +43.08% | 378B | |
| -0.72% | -0.17% | +27.13% | +16.26% | 374B | |
| -1.17% | -6.85% | +20.92% | +21.07% | 282B | |
| -0.01% | -1.64% | +27.75% | +33.63% | 278B | |
| +0.57% | +1.10% | +11.77% | -0.45% | 272B | |
| -2.23% | +0.91% | -33.46% | -20.93% | 272B | |
| +0.18% | +2.07% | +21.64% | +25.74% | 178B | |
| Average | -0.40% | +0.06% | +20.05% | +34.96% | 349.23B | |
| Weighted average by Cap. | -0.41% | -0.40% | +27.80% | +68.48% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 917B 621M 529M 490M 461M 859M 56.53B 921M 5.66B 2.24B 26.88B 2.33B 2.28B 98.09B | 1,026B 695M 592M 549M 516M 961M 63.26B 1.03B 6.34B 2.5B 30.08B 2.61B 2.55B 110B |
| Net income | 69.5B 47.07M 40.11M 37.17M 34.96M 65.06M 4.28B 69.79M 429M 169M 2.04B 176M 173M 7.43B | 80.1B 54.24M 46.23M 42.84M 40.29M 74.99M 4.94B 80.44M 494M 195M 2.35B 203M 199M 8.57B |
| Net Debt | -26.8B -18.15M -15.47M -14.33M -13.48M -25.09M -1.65B -26.91M -165M -65.36M -785M -68.06M -66.66M -2.87B | -35.6B -24.11M -20.55M -19.04M -17.91M -33.33M -2.19B -35.75M -220M -86.82M -1.04B -90.41M -88.55M -3.81B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/01/26 | 16,660.00 ₩ | +1.46% | 191,487 |
| 19/01/26 | 16,420.00 ₩ | -0.67% | 120,025 |
| 16/01/26 | 16,530.00 ₩ | -0.30% | 177,326 |
| 15/01/26 | 16,580.00 ₩ | +0.06% | 168,348 |
| 14/01/26 | 16,570.00 ₩ | -0.30% | 146,666 |
End-of-day quote Korea S.E., January 19, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- A086450 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition